A case-based approach to biologic PAs, hub coordination, denials, and reauthorizations

How should pulmonology groups track prior authorizations for asthma and COPD biologics?

TL;DR: Pulmonology groups should track asthma and COPD biologic prior authorizations as cases, not tickets, because each patient has three moving parts: the payer's PA decision, the specialty pharmacy or manufacturer hub enrollment, and the reauthorization date. Give each biologic patient one record with all three statuses, an owner, and a reauth reminder set 30 to 45 days before expiration. A pulmonology prior auth status tracking and follow-up tool should check all three threads automatically and flag pends, denials, and upcoming renewals before therapy lapses.

Why biologic PAs don't fit a normal PA workflow

A typical prior authorization is a single transaction: submit, wait, approve or deny, done. Biologics for severe asthma and COPD don't work that way.

A biologic start for a drug like dupilumab, tezepelumab, mepolizumab, benralizumab, or omalizumab usually involves the payer's PA review, a benefit investigation to determine whether the drug runs through the pharmacy or medical benefit, enrollment with a specialty pharmacy or manufacturer hub, copay assistance, and in some cases a bridge or quick-start supply. Then, six or twelve months later, it starts over with a reauthorization that requires proof the drug is working.

That's why biologic PAs stall more than other requests. A review of 326 pediatric biologic prescriptions presented at the 2026 ACAAI meeting and reported by Healio found PA was required for 93.9% of prescriptions, approval took a mean of 32.7 days (median 13), 39.3% were denied, and 28.8% needed further steps after submission. The population was pediatric patients across allergy and atopic conditions rather than adult pulmonology, but the pattern matches what biologic coordinators see every week: most requests need a PA, many don't resolve on the first pass, and the slow ones are very slow.

If you track these as single PA tickets, you'll close the ticket at approval and lose sight of the hub enrollment, the first shipment, and the reauth.

Track biologic patients as cases with three threads

The fix is structural. Each biologic patient gets one case record, and the case holds three status threads.

Thread 1: Payer authorization. Submission date, payer, benefit type (pharmacy or medical), current status, reference number, approval dates, and approved quantity or units. This is the thread most practices already track.

Thread 2: Access and fulfillment. Specialty pharmacy or hub enrollment status, benefit investigation results, copay assistance or foundation support status, bridge supply if any, and first shipment or first injection date. This is where many patients get stuck after the PA is approved.

Thread 3: Reauthorization. Approval expiration date, reauth reminder date, what documentation the payer requires to renew, and whether that documentation exists in the chart yet.

A case is only "done" when the patient is on therapy and the reauth reminder is set. Approval alone isn't the finish line.

This structure also makes ownership clearer. Many pulmonology groups assign one biologic coordinator to own all three threads for a set of patients, rather than splitting PA submission and hub coordination across different staff. The coordinator becomes the patient's single point of contact, which reduces the "who's handling this?" calls from patients and pharmacies alike.

What documentation do payers want for asthma and COPD biologics?

Most biologic pends and denials trace back to missing or outdated documentation. Knowing what payers commonly ask for lets you submit complete the first time and respond fast when they pend.

Commonly requested items for severe asthma biologics include:

  • Blood eosinophil count with the date drawn, since many policies set thresholds and lookback windows.
  • Exacerbation history, usually the number of oral corticosteroid bursts, ED visits, or hospitalizations in the prior 12 months.
  • Current controller therapy, typically high-dose inhaled corticosteroid plus a second controller, with duration and adherence notes.
  • Spirometry, often recent FEV1 values.
  • Allergy testing and total IgE for anti-IgE therapy.
  • Prescriber specialty, since some policies require a pulmonologist or allergist.

COPD biologic requests generally lean on spirometry confirming obstruction, exacerbation history despite maintenance inhaler therapy, and eosinophil counts.

For reauthorization, payers typically want evidence of response: fewer exacerbations, reduced oral steroid use, improved symptom scores or lung function, and continued adherence. If your providers don't document those outcomes at follow-up visits, the reauth will pend.

These are operational patterns, not clinical guidance. Criteria vary by payer and change often, so keep a payer-specific criteria sheet for each biologic and review it when policies update.

Build a reauthorization calendar before it builds itself

Reauthorizations are the silent revenue and adherence killer in a biologic clinic. Nobody forgets a new start; the patient is calling. Reauths get forgotten because nothing prompts them until the specialty pharmacy rejects a refill and the patient misses a dose.

A working reauth process has four parts:

  1. Capture the expiration date at approval. Put it on the case, not just in the approval letter.
  2. Set the reminder 30 to 45 days out. That leaves time to schedule a follow-up visit, document response, and submit before the old approval lapses.
  3. Check documentation readiness. At the reminder, confirm the chart contains the response measures the payer requires. If it doesn't, get the patient on the schedule.
  4. Track the reauth as its own request. Submit, check status on cadence, and close only when the new approval dates are recorded.

Run the math on your own panel. A biologic clinic with 300 active patients on annual approvals averages roughly 25 reauths a month. On six-month approvals, it's 50. Every one missed is a potential gap in therapy and a frustrated call from a patient who did nothing wrong.

Coordinate with specialty pharmacies and hubs without losing the thread

Specialty pharmacies and manufacturer hubs do valuable work, but they add channels to watch. A hub might complete the benefit investigation, the specialty pharmacy might be waiting on a signed form, and the payer might still be reviewing, all on the same day.

Practical habits that help:

  • Log every external case number (hub ID, pharmacy referral number, payer reference) on the patient's case.
  • Check the hub and pharmacy on the same cadence as the payer. A PA approval doesn't help if the pharmacy hasn't received it.
  • Watch the fax inbox. Hubs and pharmacies frequently send status updates, missing-form requests, and shipment confirmations by fax.
  • Confirm the first shipment or injection date. Close the start only when therapy begins.

Volume pressure makes this harder. The AMA's physician survey found practices complete 39 PAs per physician per week and spend 13 hours weekly on them. Biologic cases consume a disproportionate share of that time because each one has more moving parts.

Handle biologic denials and appeals as their own track

Denials are common enough in biologics that you should plan for them. In the Healio-reported review, the most frequently cited denial reasons were failing insurance criteria and required prerequisite therapy.

When a biologic is denied, read the reason carefully and sort it:

  • Missing documentation: resubmit or appeal with the specific data the payer cited.
  • Criteria not met, but clinically nuanced: request a peer-to-peer and let the physician make the case.
  • Step therapy required: confirm whether prior therapy is documented but missed, or whether a trial is truly needed.
  • Plan exclusion or non-formulary: check for formulary exceptions, alternative biologics on formulary, or manufacturer assistance.

Track each appeal as a separate item with its own deadline. And keep an eye on payer timelines: under the CMS Interoperability and Prior Authorization final rule, Medicare Advantage, Medicaid, and CHIP plans now owe decisions within 72 hours for expedited requests and 7 calendar days for standard ones, and must give a specific reason when they deny.

Where automation fits in biologic PA tracking

Biologic tracking is a strong fit for automation because so much of the work is repetitive checking and record-gathering across channels.

A pulmonology prior auth status tracking and follow-up tool built for this should check payer, hub, and pharmacy status on a schedule, read incoming faxes and attach them to the right case, alert the coordinator to pends and denials with deadlines, and generate reauth reminders from approval dates automatically.

Honey Health's Prior Authorization agent handles this kind of multi-thread tracking. It monitors open requests, pulls requested documentation such as eosinophil counts and exacerbation history from the chart, prepares responses for staff review, and keeps reauth dates from slipping. Your biologic coordinator still owns the patient relationship and the judgment calls; the agent handles the checking.

Once the case structure is in place, measure it. Track days from prescription to first dose, the share of reauths submitted before expiration, and the number of patients with a gap in therapy each month. Those three numbers tell you whether your biologic program is running on process or on heroics. If days to first dose stays long even after approvals speed up, the bottleneck is in hub enrollment or pharmacy fulfillment, not the payer, and that's where your follow-up attention should go.

Frequently Asked Questions

How long do asthma biologic prior authorizations usually take?

It varies widely by payer and drug. One 2026 conference review of pediatric biologic prescriptions found a mean of about 33 days from prescription to approval, with a median of 13 days. Federal-program plans must now decide within 72 hours (expedited) or 7 calendar days (standard), but hub enrollment and pharmacy steps add time.

How far ahead should we start a biologic reauthorization?

Start 30 to 45 days before the current approval expires. That gives time to schedule a follow-up visit if response documentation is missing, submit the reauth, and resolve any pend before the patient's next dose is due.

Who should own biologic PA tracking in a pulmonology group?

A dedicated biologic coordinator who owns the payer authorization, specialty pharmacy or hub enrollment, and reauthorization for a defined set of patients. Splitting those threads across staff is a common cause of patients falling through the gaps after approval.

What's the most common reason asthma biologics get denied?

Commonly cited reasons include not meeting the payer's clinical criteria and lack of documented prerequisite therapy. Many of these are documentation gaps rather than true clinical ineligibility, which is why complete submissions and fast responses to pends matter.

What should a biologic case record include?

At minimum: the drug and benefit type, payer and reference number, PA status and approval dates, approved quantity, specialty pharmacy or hub case number and status, copay assistance status, first dose date, reauth expiration and reminder dates, the case owner, and the next action with its due date.

Should biologic PAs be tracked separately from other pulmonology PAs?

They should at least have a dedicated view. Biologics involve hubs, pharmacies, copay programs, and recurring reauthorizations that other PAs don't, so they need case-level tracking. They can still live in the same overall queue as DME, sleep, and imaging requests.

More of our Article
CLINIC TYPE
LOCATION
INTEGRATIONS
More of our Article and Stories